Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 155,699 shares, a growth of 80.5% from the September 15th total of 86,259 shares. Based on an average daily trading volume, of 401,756 shares, the short-interest ratio is currently 0.4 days.
Tevogen Bio Stock Performance
Shares of TVGNW traded down $0.00 during mid-day trading on Friday, reaching $0.07. 4,487 shares of the company’s stock traded hands, compared to its average volume of 220,044. The business’s 50-day moving average price is $0.06 and its 200-day moving average price is $0.05. Tevogen Bio has a 12 month low of $0.03 and a 12 month high of $0.08.
About Tevogen Bio
Tevogen Bio Holdings Inc is a clinical-stage biotechnology company focused on developing off-the-shelf T-cell therapies for patients with infectious diseases, cancer and neurological disorders. The company’s approach uses genetically selected, naturally occurring virus-specific cytotoxic T cells intended to target diseased cells while limiting damage to healthy tissue.
Tevogen’s lead investigational product, TVGN 489, is an allogeneic, SARS-CoV-2-specific T-cell therapy being developed for immunocompromised patients who may remain vulnerable to COVID-19 despite vaccination or other treatments.
Read More
- Five stocks we like better than Tevogen Bio
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
- Palantir’s Potential Next Catalyst After Retail Profit-Taking
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
